ID   D-542MG
AC   CVCL_1164
SY   D542MG
DR   CLO; CLO_0009889
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 854
DR   cancercelllines; CVCL_1164
DR   Cell_Model_Passport; SIDM00207
DR   ChEMBL-Cells; CHEMBL3308259
DR   ChEMBL-Targets; CHEMBL2366208
DR   Cosmic; 753549
DR   Cosmic; 2367521
DR   Cosmic-CLP; 753549
DR   DepMap; ACH-002230
DR   EGA; EGAS00001000978
DR   GDSC; 753549
DR   GEO; GSM1669722
DR   IARC_TP53; 21297
DR   LINCS_LDP; LCL-1376
DR   PharmacoDB; D542MG_278_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1164
DR   Wikidata; Q54817139
RX   PubMed=10402232;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Asian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg335Ter (c.1003C>T); ClinVar=VCV000007833; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg556Ter (c.1666C>T); ClinVar=VCV000013090; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.45%; Native American=2.46%; East Asian, North=53.35%; East Asian, South=39.58%; South Asian=0%; European, North=1%; European, South=3.16% (PubMed=30894373).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 10
ST   D16S539: 10,13
ST   D5S818: 10,12
ST   D7S820: 9,11
ST   TH01: 6,9
ST   TPOX: 11
ST   vWA: 18
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VU88 ! L542
SX   Female
AG   Adult
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 32
//
RX   PubMed=10402232; DOI=10.3892/ijo.15.2.237;
RA   Sharif T.R., Sharif M.;
RT   "Overexpression of protein kinase C epsilon in astroglial brain tumor
RT   derived cell lines and primary tumor samples.";
RL   Int. J. Oncol. 15:237-243(1999).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//